Issue 6/2014
Content (23 Articles)
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel
John Sarantopoulos, Alain C. Mita, James L. Wade, John C. Morris, Olivier Rixe, Monica M. Mita, Jean-François Dedieu, Claudine Wack, Laurent Kassalow, A. Craig Lockhart
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models
Ute Hoch, Carl-Michael Staschen, Randall K. Johnson, Michael A. Eldon
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study
Nuriye Ozdemir, Huseyin Abali, Murat Vural, Suayib Yalcin, Berna Oksuzoglu, Burak Civelek, Dilek Oguz, Birol Bostanci, Bulent Yalcin, Nurullah Zengin
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902
Kenya Kanazawa, Hiroshi Yokouchi, Xintao Wang, Takashi Ishida, Yuka Fujita, Satoru Fujiuchi, Toshiyuki Harada, Masao Harada, Kei Takamura, Satoshi Oizumi, Ichiro Kinoshita, Yutaka Katsuura, Osamu Honjo, Tetsuya Kojima, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Mitsuru Munakata, Masaharu Nishimura
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease
Ryoko Shimizu, Daichi Fujimoto, Ryoji Kato, Takehiro Otoshi, Takahisa Kawamura, Koji Tamai, Takeshi Matsumoto, Kazuma Nagata, Kyoko Otsuka, Atsushi Nakagawa, Kojiro Otsuka, Nobuyuki Katakami, Keisuke Tomii
Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages
Helena Taflin, Yvonne Wettergren, Elisabeth Odin, Kristoffer Derwinger
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors
R. C. Brennan, W. Furman, S. Mao, J. Wu, D. C. Turner, C. F. Stewart, V. Santana, L. M. McGregor
Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
Makoto Sonobe, Ken-ichi Okubo, Satoshi Teramukai, Kazuhiro Yanagihara, Masaaki Sato, Toshihiko Sato, Fengshi Chen, Kiyoshi Sato, Takuji Fujinaga, Tsuyoshi Shoji, Mitsugu Omasa, Hiroaki Sakai, Ryo Miyahara, Toru Bando, Hiroshi Date
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy
Tsuyoshi Shirakawa, Ken Kato, Kengo Nagashima, Akiko Nishikawa, Ryoichi Sawada, Naoki Takahashi, Hirokazu Shoji, Yusuke Sasaki, Yoshitaka Honma, Satoru Iwasa, Atsuo Takashima, Natsuko Okita, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada
Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer
V. Georgoulias, S. Apostolaki, V. Bozionelou, E. Politaki, M. Perraki, N. Georgoulia, K. Kalbakis, A. Kotsakis, A. Xyrafas, S. Agelaki, D. Mavroudis
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors
Caroline I. Piatek, Grace L. Raja, Lingyun Ji, Barbara Jennifer Gitlitz, Tanya B. Dorff, David I. Quinn, James Hu, Anthony B. El-Khoueiry, Huyen Q. Pham, Lynda Roman, Agustin A. Garcia
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer
Toru Aoyama, Yusuke Katayama, Masaaki Murakawa, Masahiro Asari, Amane Kanazawa, Akio Higuchi, Manabu Shiozawa, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Shinnichi Ohkawa, Makoto Akaike, Naoto Yamamoto, Takaki Yoshikawa, Yasushi Rino, Munetaka Masuda, Soichiro Morinaga
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
Devalingam Mahalingam, John J. Nemunaitis, Laeeq Malik, John Sarantopoulos, Steven Weitman, Kamalesh Sankhala, Jessica Hart, Ahmed Kousba, Nicole S. Gallegos, Gavin Anderson, John Charles, Jon M. Rogers, Neil N. Senzer, Alain C. Mita
Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
Na Xu, Charles H. Redfern, Michael Gordon, Stephen Eppler, Bert L. Lum, Caroline Trudeau
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses
E. E. W. Cohen, M. Tortorici, S. Kim, A. Ingrosso, Y. K. Pithavala, P. Bycott
Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies
Joel M. Reid, Matthew P. Goetz, Sarah A. Buhrow, Chad Walden, Stephanie L. Safgren, Mary J. Kuffel, Kathryn E. Reinicke, Vera Suman, Paul Haluska, Xiaonan Hou, Matthew M. Ames
Pharmacokinetics of single-agent axitinib across multiple solid tumor types
Michael A. Tortorici, Ezra E. W. Cohen, Yazdi K. Pithavala, May Garrett, Ana Ruiz-Garcia, Sinil Kim, John P. Fruehauf
Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis
In Gyu Hwang, Hong Suk Song, Myung Ah Lee, Eun Mi Nam, Joohan Lim, Kyung Hee Lee, Kyu Taek Lee, Dae Young Zang, Joung-Soon Jang
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
Heyan Li, Koichi Takayama, Shuo Wang, Yoshimasa Shiraishi, Keisuke Gotanda, Taishi Harada, Kazuto Furuyama, Eiji Iwama, Ichiro Ieiri, Isamu Okamoto, Yoichi Nakanishi
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial
V. Gotta, N. Widmer, L. A. Decosterd, Y. Chalandon, D. Heim, M. Gregor, R. Benz, L. Leoncini-Franscini, G. M. Baerlocher, M. A. Duchosal, C. Csajka, T. Buclin
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report
Toshinori Sueda, Toshihiro Kudo, Daisuke Sakai, Mamoru Uemura, Junichi Nishimura, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Hirofumi Yamamoto, Sachiko Ezoe, Kana Matsumoto, Yuichiro Doki, Masaki Mori, Taroh Satoh